Evidence map›Paper›PMID 33467442›Full record

ArticleCancers2021

Soluble and Exosome-Bound α-Galactosylceramide Mediate Preferential Proliferation of Educated NK Cells with Increased Anti-Tumor Capacity.

Arnika K Wagner, Ulf Gehrmann, Stefanie Hiltbrunner, Valentina Carannante, Thuy T Luu, Tanja I Näslund, Hanna Brauner, Nadir Kadri, Klas Kärre, Susanne Gabrielsson

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Secretory exosomes from modified immune cells against cancer.Medical oncology (Northwood, London, England) · 2025
    Review
  3. Article
  4. Review
  5. Targeting Sphingolipids for Cancer Therapy.Frontiers in oncology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Arnika K WagnerDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-17165 Stockholm, Sweden.ORCID 0000-0002-0339-8259
Ulf GehrmannDivision of Immunology and Allergy, Department of Medicine, Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden.
Stefanie HiltbrunnerDivision of Immunology and Allergy, Department of Medicine, Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden.
Valentina CarannanteDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-17165 Stockholm, Sweden.ORCID 0000-0003-4464-7087
Thuy T LuuCenter for Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, SE-14186 Stockholm, Sweden.ORCID 0000-0002-2619-1357
Tanja I NäslundDivision of Immunology and Allergy, Department of Medicine, Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden.
Hanna BraunerDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-17165 Stockholm, Sweden.ORCID 0000-0003-2810-4189
Nadir KadriCenter for Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, SE-14186 Stockholm, Sweden.
Klas KärreDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-17165 Stockholm, Sweden.
Susanne GabrielssonDivision of Immunology and Allergy, Department of Medicine, Solna, Karolinska Institutet, SE-17176 Stockholm, Sweden.ORCID 0000-0003-1771-1346
Karolinska Institutet · SEKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells can kill target cells via the recognition of stress molecules and down-regulation of major histocompatibility complex class I (MHC-I). Some NK cells are educated to recognize and kill cells that have lost their MHC-I expression, e.g., tumor or virus-infected cells. A desired property of cancer immunotherapy is, therefore, to activate educated NK cells during anti-tumor responses in vivo. We here analyze NK cell responses to α-galactosylceramide (αGC), a potent activator of invariant NKT (iNKT) cells, or to exosomes loaded with αGC. In mouse strains which express different MHC-I alleles using an extended NK cell flow cytometry panel, we show that αGC induces a biased NK cell proliferation of educated NK cells. Importantly, iNKT cell-induced activation of NK cells selectively increased in vivo missing self-responses, leading to more effective rejection of tumor cells. Exosomes from antigen-presenting cells are attractive anti-cancer therapy tools as they may induce both innate and adaptive immune responses, thereby addressing the hurdle of tumor heterogeneity. Adding αGC to antigen-loaded dendritic-cell-derived exosomes also led to an increase in missing self-responses in addition to boosted T and B cell responses. This study manifests αGC as an attractive adjuvant in cancer immunotherapy, as it increases the functional capacity of educated NK cells and enhances the innate, missing self-based antitumor response.

Indexed as

antitumor immunityexosomesextracellular vesiclesinnate anti-tumor responseMHC class Imissing-self responsenatural killer (NK) cellsNK cell education

Identifiers

PMID33467442
PMCPMC7830699
OpenAlexW3120280692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.